CXCL8 and cancer: Recently, selective inhibitors of IL-1β, IL-6 and IL-8 are proposed in cancer patients aimed to improve anticancer effects of selective inhibitors of kinases and immune check-point inhibitors, reducing their toxicity (108, 109).